Quest Diagnostics Incorporated (DGX)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
As of 02:39PM EDT. Market open.
| Previous Close | 135.42 |
| Open | 135.00 |
| Bid | 134.87 x 800 |
| Ask | 134.97 x 800 |
| Day's Range | 134.53 - 135.99 |
| 52 Week Range | 119.59 - 145.58 |
| Volume | |
| Avg. Volume | 1,053,914 |
| Market Cap | 14.979B |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | 18.15 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.00 (2.22%) |
| Ex-Dividend Date | Apr 05, 2024 |
| 1y Target Est | N/A |
- ACCESSWIRE
Quest Diagnostics Foundation and Green Bronx Machine Expand Collaboration to Bring Acclaimed Indoor Gardening Curriculum to More Communities and Raise Awareness for Impact of Nutrition Education on Health Equity
Foundation grant will help NYC-based nonprofit expand reach of its innovative curriculum to 50 schools in Baltimore and Houston; funding will also support film screening tour of award-winning documentary to highlight importance of health equity through ...
- PR Newswire
Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2024.
- PR Newswire
Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the launch of a new blood biomarker test for phosphorylated tau 217, or p-tau217. P-tau217 is a biomarker associated with Alzheimer's Disease (AD), supported by research as useful for an early diagnosis of AD.
© 2024 Yahoo. All rights reserved.